Half-year report · Q2
3353.TEDINET S100UIUM
Period2024-03-01 → 2024-08-31
Filed2024-10-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥22.7bn | 2024-03-01 → 2024-08-31 | Cons. | Net sales |
| Revenue | ¥39.9bn | 2023-03-01 → 2024-02-29 | Cons. | Net sales (5-year summary) |
| Revenue | ¥17.5bn | 2023-03-01 → 2023-08-31 | Cons. | Net sales |
| Operating income | ¥828m | 2024-03-01 → 2024-08-31 | Cons. | Operating income |
| Operating income | ¥603m | 2023-03-01 → 2023-08-31 | Cons. | Operating income |
| Ordinary income | ¥853m | 2024-03-01 → 2024-08-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.8bn | 2023-03-01 → 2024-02-29 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥697m | 2023-03-01 → 2023-08-31 | Cons. | Ordinary income |
| Profit before tax | ¥1.1bn | 2024-03-01 → 2024-08-31 | Cons. | Income before income taxes |
| Profit before tax | ¥776m | 2023-03-01 → 2023-08-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥710m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.0bn | 2023-03-01 → 2024-02-29 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥444m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥728m | 2024-03-01 → 2024-08-31 | Cons. | Profit loss |
| Net income | ¥469m | 2023-03-01 → 2023-08-31 | Cons. | Profit loss |
| Total assets | ¥33.1bn | at 2024-08-31 | Cons. | Assets |
| Total assets | ¥31.7bn | at 2024-02-29 | Cons. | Assets |
| Total assets | ¥28.5bn | at 2023-08-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥18.7bn | at 2024-08-31 | Cons. | Liabilities |
| Total liabilities | ¥17.8bn | at 2024-02-29 | Cons. | Liabilities |
| Net assets / equity | ¥14.4bn | at 2024-08-31 | Cons. | Net assets |
| Net assets / equity | ¥13.8bn | at 2024-02-29 | Cons. | Net assets |
| Net assets / equity | ¥13.1bn | at 2023-08-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥8.2bn | at 2024-08-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥7.7bn | at 2024-02-29 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.1bn | at 2024-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.6bn | at 2024-02-29 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.5bn | at 2023-08-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥6.3bn | at 2023-02-28d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥1.5bn | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥4.3bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥848m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥675m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥3.2bn | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥338m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥354m | 2024-03-01 → 2024-08-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥278m | 2023-03-01 → 2024-02-29 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥217m | 2023-03-01 → 2023-08-31 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥188.75 | 2024-03-01 → 2024-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥276.7 | 2023-03-01 → 2024-02-29 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥118.26 | 2023-03-01 → 2023-08-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 41.6% | at 2024-08-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 41.8% | at 2024-02-29 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 43.9% | at 2023-08-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2024-08-31 | −¥401m |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2024-08-31 | −¥110m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥551m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥4.0bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥128m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥7.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥6.7bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥399m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥194m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2024-03-01 → 2024-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2024-03-01 → 2024-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2024-03-01 → 2024-08-31 | ¥65m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-03-01 → 2024-08-31 | ¥23.1bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-03-01 → 2024-08-31 | ¥22.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-03-01 → 2024-08-31 | ¥401m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-03-01 → 2024-08-31 | ¥938m |
| Reconciling Itemsreconciling | revenue | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | revenue intersegment | 2023-03-01 → 2023-08-31 | −¥472m |
| Reconciling Itemsreconciling | segment profit | 2023-03-01 → 2023-08-31 | −¥296m |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥11.9bn |
| jpcrp040300-q2r_E03443-000Dispensing Pharmacyreportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥688m |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥3.9bn |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥300,000 |
| jpcrp040300-q2r_E03443-000Health Carereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥111m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥2.1bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥1.6bn |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥470m |
| jpcrp040300-q2r_E03443-000Medical Products Wholesalereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥34m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue | 2023-03-01 → 2023-08-31 | ¥93m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue external | 2023-03-01 → 2023-08-31 | ¥91m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥2m |
| jpcrp040300-q2r_E03443-000Real Estatereportable segment | segment profit | 2023-03-01 → 2023-08-31 | ¥66m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-03-01 → 2023-08-31 | ¥17.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-03-01 → 2023-08-31 | ¥17.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-03-01 → 2023-08-31 | ¥472m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-03-01 → 2023-08-31 | ¥899m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 515
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision of allowance for doubtful accounts sga | Prior1YTDDuration | 185000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYTDDuration | 3972000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11861141000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3899552000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 1598645000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 91141000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 17450480000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 17450480000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 300000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 469627000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 2327000 | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 472254000 | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | -472254000 | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11861141000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3899852000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 2068272000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 93468000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 17922735000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | -472254000 | JPY |
| Net sales | Prior1YTDDuration | 17450480000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 688191000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 110740000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 33863000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 66084000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 898880000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | -295826000 | JPY |
| Operating income | Prior1YTDDuration | 603054000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11911592000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3962013000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 6701052000 | JPY |
| Revenues from external customers | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 90787000 | JPY |
| Revenues from external customers | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 22665446000 | JPY |
| Revenues from external customers | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | CurrentYTDDuration | 22665446000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | － | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 300000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 398765000 | JPY |
| Transactions with other segments | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 2327000 | JPY |
| Transactions with other segments | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 401393000 | JPY |
| Transactions with other segments | CurrentYTDDuration_ReconcilingItemsMember | -401393000 | JPY |
| Transactions with other segments | CurrentYTDDuration | － | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000DispensingPharmacyReportableSegmentsMember | 11911592000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000HealthCareReportableSegmentsMember | 3962313000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000MedicalProductsWholesaleReportableSegmentsMember | 7099818000 | JPY |
| Net sales | CurrentYTDDuration_jpcrp040300-q2r_E03443-000RealEstateReportableSegmentsMember | 93115000 | JPY |
| Net sales | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 23066839000 | JPY |
| Net sales | CurrentYTDDuration_ReconcilingItemsMember | -401393000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |